english.prescrire.org > Spotlight > 100 most recent > Tezepelumab (Tezspire°) in severe asthma in adults and adolescents


Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Tezepelumab (Tezspire°) in severe asthma in adults and adolescents

 Marketing Authorisations   Tezepelumab is a monoclonal antibody that binds to the cytokine thymic stromal lymphopoietin. It has been authorised in the European Union for use in adults and adolescents with severe asthma, as an add-on to insufficiently effective maintenance treatment with a high-dose inhaled corticosteroid combined with at least one other drug. In this situation, is tezepelumab more effective than an oral corticosteroid or any of the other monoclonal antibodies authorised in asthma, does it help reduce patients’ oral corticosteroid requirements, and what are its adverse effects?
Full article available for download by subscribers (4 pages)

©Prescrire 1 May 2024

Source: "Tezepelumab (Tezspire°) in severe asthma in adults and adolescents" Prescrire Int 2024; 33 (259): 117-120. Subscribers only.

Enjoy full access to Prescrire International, and support independent information


Share on  Facebook Share on  Twitter
See also:

"A difficult choice"
Prescrire Int 2023;
32 (248): 115.

"Dupilumab (Dupixent°)
in severe asthma from
6 years of age"
Prescrire Int 2023;